Download preclinical models for drug development in human prostate cancer

Technology Transfer Office
www.erasmusmc.nl/tto
PRECLINICAL MODELS FOR DRUG
DEVELOPMENT IN HUMAN PROSTATE CANCER
ERASMUS MC has developed an unique set of tools for the study of human prostate
cancer, which include cell lines, patient-derived xenografts and 3D cultures.
Prostate cancer is the second most common cancer
in men worldwide. More than 1.1 million cases of
prostate cancer are reported annually, which
accounts for 15% of all new cancer cases in men.
Current treatments show considerable variability.
Hence, new therapies are strongly needed.
cancer to castration-resistance disease and
express different mutations and androgendependent properties.
 Human prostate cancer cell lines Besides our
own cell lines, we have all relevant humanderived prostate cancer cells lines routinely
available in our laboratory.
THE TECHNOLOGIES
ADVANTAGES & APPLICATIONS
ERASMUS MC has developed various experimental
models systems to perform preclinical research in
human prostate cancer. All materials are ready to
use. The materials comprise:
 Patient-derived xenografts (PDX) and 3D cultures
A unique set of 13 androgen-responsive, and resistant prostate cancer PDX that represent
the various stages of the clinical disease. From 2
PDX models, docetaxel-resistance have been
established in vivo of which corresponding 3D
spheroid cultures are tumorigenic in mice.
 Spontaneous metastatic model A metastatic
PDX-derived model showing spontaneous
development of liver metastasis after
subcutaneous and orthotopic inoculation. Liver
metastases
develop
consistently
with
metastatic spread to lung, lymph nodes and
bone. These metastatic lesions have been
cultured to retrieve metastatic sublines.
 Co-culture model Complex co-culture system
that allows to explore the steroidal biology of
CRPC and test compounds that inhibit the
synthesis of androgens. This model is extended
in vivo to create an endocrinological humanized
PDX model.
 Castration-resistant prostate cancer (CRPC) cell
lines A panel of 4 cell lines, with several sublines
each, that mimic clinical progression of prostate
 Sensitive models to study prostate cancer
 Research tool to identify and elucidate signaling
molecular pathways and new targets
 Drug development by allowing screening and
validation of candidate drugs
THE CHALLENGE
CONTACT
These tools may ultimately facilitate the
development of new drugs for the treatment of
prostate cancer.
COMMERCIAL OPPORTUNITY
E RASMUS MC is actively searching for a partner for
out-licensing of the technology. Interested parties
are kindly invited to contact ERASMUS MC
Technology Transfer Office (please see contact
details below) to further explore the possibilities of
partnership.
REFERENCES
MARQUES et al. High efficacy of combination
therapy using PI3K/AKT inhibitors with androgen
deprivation in prostate cancer preclinical models
(2015) European Urology 67(6):1177-85.
WEERDEN et al. Human xenograft models as
useful tools to access the potential of novel
therapeutics in prostate cancer (2009) British
Journal of Cancer 100:13-18.
VAN
JAVIERA ESPOZ , MSc ([email protected]; +31 107038818)
Jr. Business Development Manager
Technology Transfer Office
ERASMUS MC, ROTTERDAM, THE NETHERLANDS
– NON-CONFIDENTIAL DISCLOSURE –